EGFR and non-small cell lung carcinoma: In NSCLC patients, previous studies have proved that these mutations are associated with a favorable response to first-line treatment with EGFR-TKIs, such as gefitinib, erlotinib and afatinib, compared to standard chemotherapy in NSCLC [5,6,7].